Moderna Inc. [NASDAQ: MRNA] price surged by 12.20 percent to reach at $15.98. The company report on January 25, 2021 that Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25.
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it will hold a conference call, Monday, January 25 at 4:30 pm ET on the Company’s announcement that results from in vitro neutralization studies of sera from individuals vaccinated with Moderna COVID-19 Vaccine showing activity against emerging strains of SARS-CoV-2.
To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international) and refer to conference ID 6346618. A webcast of the call will also be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. The archived webcast will be available on Moderna’s website approximately two hours after the conference call and will be available for one year following the call.
A sum of 26891585 shares traded at recent session while its average daily volume was at 23.39M shares. Moderna Inc. shares reached a high of $147.4299 and dropped to a low of $137.25 until finishing in the latest session at $147.00.
The one-year MRNA stock forecast points to a potential downside of -1.81. The average equity rating for MRNA stock is currently 2.50, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Moderna Inc. [MRNA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRNA shares is $144.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRNA stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Moderna Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on December 16, 2020. While these analysts kept the previous recommendation, Jefferies dropped their target price from $90 to $150. The new note on the price target was released on December 16, 2020, representing the official price target for Moderna Inc. stock.
The Average True Range (ATR) for Moderna Inc. is set at 9.84, with the Price to Sales ratio for MRNA stock in the period of the last 12 months amounting to 239.32. The Price to Book ratio for the last quarter was 21.03, with the Price to Cash per share for the same quarter was set at 8.16. Price to Free Cash Flow for MRNA in the course of the last twelve months was 96.33 with Quick ratio for the last quarter at 2.40.
MRNA Stock Performance Analysis:
Moderna Inc. [MRNA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.38. With this latest performance, MRNA shares gained by 16.78% in over the last four-week period, additionally plugging by 100.79% over the last 6 months – not to mention a rise of 596.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRNA stock in for the last two-week period is set at 65.13, with the RSI for the last a single of trading hit 72.42, and the three-weeks RSI is set at 61.93 for Moderna Inc. [MRNA]. The present Moving Average for the last 50 days of trading for this stock 124.90, while it was recorded at 132.23 for the last single week of trading, and 80.21 for the last 200 days.
Insight into Moderna Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Moderna Inc. [MRNA] shares currently have an operating margin of -906.38. Moderna Inc.’s Net Margin is presently recorded at -853.73.
Return on Total Capital for MRNA is now -37.83, given the latest momentum, and Return on Invested Capital for the company is -35.81. Return on Equity for this stock declined to -38.00, with Return on Assets sitting at -28.95. When it comes to the capital structure of this company, Moderna Inc. [MRNA] has a Total Debt to Total Equity ratio set at 11.57. Additionally, MRNA Total Debt to Total Capital is recorded at 10.37, with Total Debt to Total Assets ending up at 8.55. Long-Term Debt to Equity for the company is recorded at 11.27, with the Long-Term Debt to Total Capital now at 10.10.
Reflecting on the efficiency of the workforce at the company, Moderna Inc. [MRNA] managed to generate an average of -$619,302 per employee. Receivables Turnover for the company is 2.57 with a Total Asset Turnover recorded at a value of 0.03.Moderna Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.40.
MRNA Stock EPS
With the latest financial reports released by the company, Moderna Inc. posted -0.37/share EPS, while the average EPS was predicted by analysts to be reported at -0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 11.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRNA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Moderna Inc. go to 16.80%.
Moderna Inc. [MRNA] Insider Position Details
There are presently around $29,882 million, or 52.00% of MRNA stock, in the hands of institutional investors. The top three institutional holders of MRNA stocks are: FMR LLC with ownership of 34,221,324, which is approximately -8.821% of the company’s market cap and around 2.10% of the total institutional ownership; FLAGSHIP PIONEERING INC., holding 30,871,524 shares of the stock with an approximate value of $4.54 billion in MRNA stocks shares; and VANGUARD GROUP INC, currently with $4.1 billion in MRNA stock with ownership of nearly 8.779% of the company’s market capitalization.
Positions in Moderna Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 369 institutional holders increased their position in Moderna Inc. [NASDAQ:MRNA] by around 15,328,851 shares. Additionally, 211 investors decreased positions by around 28,870,605 shares, while 49 investors held positions by with 159,076,407 shares. The mentioned changes placed institutional holdings at 203,275,863 shares, according to the latest SEC report filing. MRNA stock had 152 new institutional investments in for a total of 2,303,021 shares, while 68 institutional investors sold positions of 3,373,537 shares during the same period.